Exyte acquires TTP Group to accelerate growth of Biopharma and Life Sciences business

The goal is to create a strong partner for the booming European biotechnology and pharmaceutical industry

10-Sep-2024 - Exyte, a global leader in the design, engineering, and delivery of high-tech facilities, intends to acquire TTP Group ("TTP"), a leading firm in consulting and engineering for the pharmaceutical and chemical industry in Europe. TTP's portfolio encompasses a wide range of engineering services, ...

When does it make sense to develop a new therapeutic agent?

Criteria that research must meet so that a substance that shows promise in the laboratory can actually be developed into a clinically effective drug

23-Nov-2020 - Scientists from the Berlin Institute of Health (BIH) and Charité – Universitätsmedizin Berlin, along with colleagues from the Fraunhofer Institute for Molecular Biology and Applied Ecology (IME-TMP) in Frankfurt am Main and PAASP GmbH in Heidelberg, have compiled a catalogue of recommendations ...

Improving research with more effective antibodies

Scientists demonstrate flaws in protein detection tools, and outline a solution

17-Oct-2019 - A new study points to the need for better antibody validation, and outlines a process that other labs can use to make sure the antibodies they work with function properly. Antibodies are used in laboratories and clinics to study proteins, which are the biomolecules that translate information from ...

IIVS Collaborates with BASF and Givaudan to Validate a Non-animal Test for Regulatory Submissions

29-Aug-2018 - The Institute for In Vitro Sciences (IIVS), with an established track record in the validation of alternatives to animal testing, is teaming up with BASF and Givaudan to validate an improved skin sensitization reactivity method to address the needs of toxicologists and regulators. Scientists at ...

Genetic model identifies primary myelofibrosis outcomes

11-Dec-2017 - A group of investigators from Mayo Clinic and multiple academic research centers in Italy have identified a genetic model for predicting outcomes in patients with primary myelofibrosis who are 70 years or younger and candidates for stem cell transplant to treat their disease. The group's findings ...

Horizon Discovery Group and Ventana Medical Systems sign co-development agreement

02-Sep-2016 - Horizon Discovery Group plc announces it has entered into a co-development and commercialisation agreement with Ventana Medical Systems, Inc., a member of the Roche Group. The Agreement covers the development, manufacture and commercialisation of cell line derivative materials for use as IHC ...

Affimed enrolls first patients in Phase I Hodgkin's Lymphoma Study

17-Nov-2010 - Affimed Therapeutics AG announced that the first patients with Hodgkin's Lymphoma have been treated with the AFM13 TandAb® antibody in a Phase I clinical study. The Phase I repeat dose escalation study will enroll approximately 40 Hodgkin's Lymphoma patients across two centers in Europe and the ...

Singapore Launches Infrastructure for Metrology in Chemistry (MiC)

04-Nov-2010 - The National Metrology Centre (NMC) of the Agency for Science, Technology and Research (A*STAR) and the Health Sciences Authority (HSA) have jointly set up a national Metrology in Chemistry (MiC) infrastructure. Senior Minister of State for Trade and Industry and Education, Mr S. Iswaran ...

Dako and Quintiles form alliance to speed development of personalized medicine

02-Nov-2010 - Dako and Quintiles announced a strategic alliance to advance personalized medicine by collaborating on the co-development of targeted therapies and companion diagnostics. Under the non-exclusive alliance, Dako and Quintiles will offer integrated drug-diagnostic development services and companion ...

Epigenomics AG: New Clinical Data for Septin9 Colorectal Cancer Blood Test

Independent validation of laboratory test used in PRESEPT Study shows that the test finds 86% of the cancers

29-Oct-2010 - Epigenomics AG announced that new data obtained in a clinical study with the Company's proprietary Septin9 biomarker for the blood-based detection of colorectal cancer were presented at the 18th United European Gastroenterology Week (UEGW) in Barcelona, Spain. The new data were presented by Dr. ...